{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Percutaneous Laser Ablation for Invasive Ductal Breast Carcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "multicenter, open-label, phase 2 trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "women aged 18-80 with a single focus of IDC \u226420 mm were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants underwent PLA, followed by a 28-day post-ablation MRI and surgical resection"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed the efficacy of percutaneous laser ablation (PLA) for invasive ductal carcinoma (IDC)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was complete tumor ablation, evaluated by pathology"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and blinding were not applicable"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between June 2012 and May 2015, 61 patients were treated"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Complete tumor ablation was confirmed in 51 (84%) patients"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "MRI negative predictive value of 92.2% (95% CI, 71.9\u201391.9%)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild to moderate, with no serious events reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}